Bridging the pathophysiology of Alzheimer's disease with vascular pathology: The feed-back, the feed-forward, and oxidative stress

Journal of Alzheimer's Disease

Volumn 28, Issue 1, 2012, Pages 1-9

  Polidori, M Cristina ^a   Pientka, Ludger ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Alzheimer's disease; oxidative stress; vascular pathology

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM ANTAGONIST; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVACECARNINE; NONSTEROID ANTIINFLAMMATORY AGENT; SELEGILINE;

ALZHEIMER DISEASE; DRUG MECHANISM; EX VIVO STUDY; FEEDBACK SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE FEEDBACK; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VASCULARIZATION;

EID: 84855815646     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111034     Document Type: Review

References (66)

1. de La Torre JC (2002) Alzheimers disease: How does it start?. J Alzheimers Dis 4, 497-512.
2. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, Luchsinger JA, Ogunniyi A, Perry EK (2008) Alzheimers disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet Neurol 7, 812-826.
3. Breteler MM, Bots ML, Ott A, Hofman A (1998) Risk factors for vascular disease and dementia. Haemostasis 28, 167-173. (Pubitemid 29309598)
4. Breteler MM (2000) Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann NY Acad Sci 903, 457-465. (Pubitemid 30251589)
5. Freyham FA, Woodford WB, Kety SS (1951) Cerebral blood flow and metabolism in psychosis of senility. J Nerv Ment Dis 113, 455-456.
6. Lassen NA, Munck O, Tottery ER (1957) Mental function and cerebral oxygen consumption in organic dementia. Arch Neurol Psychiatry 77, 126-133.
7. Hachinski VC, Iliff LD, Zihlkas E, Du Boulay GH, McAllister VL, Marshall J, Ross Russell RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32, 632-637.
8. Morris JC (1994) Differential diagnosis of Alzheimers disease. Clin Geriatr Med 10, 257-276.
9. Vagnucci AH, LiWW(2003) Alzheimers disease and angiogenesis. Lancet 361, 605-608.
10. De la Torre JC (2000) Critically attained threshold of cerebral hypoperfusion: The CATCH hypothesis of Alzheimers pathogenesis. Neurobiol Aging 21, 331-342. (Pubitemid 30387092)
11. Skoog I, Kalaria RN, Breteler MM (1999) Vascular factors and Alzheimers disease. Alzh Dis Assoc Disord 13, S106-S114.
12. Kalaria RN, Ballard C (1999) Overlap between pathology of Alzheimer Disease and vascular dementia. Alz Dis Assoc Disord 13, S115-S123.
13. Kalaria RN, Ince P (2000) Vascular factors in Alzheimers Disease. Ann NY Acad Sci 903, The New York Academy of Sciences, New York, pp. 1-552.
14. Smith MA, Casadesus G (2009) Walking toward a convergence in aging research. Front Neurosc 3, 1.
15. Siegrist J (2002) Effort-reward Imbalance at work and health. In: Research in Occupational Stress and Well Being, Vol. 2: Historical and Current Perspectives on Stress and Health, Perrewe P, Ganster D, Eds. Elsevier, New York, pp. 261-291.
16. Sparks DL, Hunsaker JC III, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR (1990) Cortical senile plaques in coronary artery disease, aging and Alzheimers disease. Neurobiol Aging 11, 601-607.
17. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90, 1977-1981. (Pubitemid 23069980)
18. de la Torre JC, Mussivand T (1993) Can disturbed brain microcirculation cause Alzheimers disease? Neurol Res 15, 146-153. (Pubitemid 23166998)
19. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimers disease. Nat Rev Neurosci 5, 347-360. (Pubitemid 38568496)
20. Niedermeyer E (2006) Alzheimer disease caused by primary deficiency of the cerebral blood flow. Clin Electroencephalogr Neurosci 37, 175-177. (Pubitemid 44222857)
21. Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, Gasimov EK, Vinters HV, Perry G, LaManna JC, Friedland RP (2002) The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimers disease. Brain Pathol 12, 21-35. (Pubitemid 33131359)
22. Sparks DL (2008) The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimers disease: The old, the new and the pilot. J Alzheimers Dis 15, 641-656.
23. StrittmatterWJ(2001) Apolipoprotein E and Alzheimers disease: Signal transduction mechanisms. Biochem Soc Symp 67, 101-109. (Pubitemid 33602678)
24. de la Torre JC (2011) Three postulates to help identify the cause of Alzheimers disease. J Alzheimers Dis 24, 657-668.
25. Iadecola C (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120, 287-296.
26. Mazza M, Marano G, Traversi G, Bria P, Mazza S (2011) Alzheimer disease: Primary cerebral blood flow deficiency and Alzheimers disease: Shadows and lights. J Alzheimers Dis 23, 375-389.
27. Aliev G, Obrenovich ME, Reddy VP, Shenk JC, Moreira PI, Nunomura A, Zhu X, Smith MA, Perry G (2008) Antioxidant therapy in Alzheimer disease: Theory and practice. Mini Rev Med Chem 8, 1395-1406.
28. Polidori MC, Marvardi M, Cherubini A, Senin U, Mecocci P (2001) Heart disease and vascular risk factors in the cognitively impaired elderly: Implications for Alzheimers dementia. Aging 13, 231-239. (Pubitemid 32600089)
29. Knopman DS, Roberts R (2010) Vascular risk factors: Imaging and neuropathological correlates. J Alzheimers Dis 20 699-709.
30. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissien A (2001) Midlife vascular risk factors and Alzheimers disease in later life: Longitudinal, population based study. BMJ 322, 1447-1451. (Pubitemid 32575406)
31. Polidori MC, Pientka L, Nelles G, Griffiths HR (2010) Modulation of cholesterol in midlife affords cognitive advantage during ageing -a role for altered redox balance. Int J Clin Exp Med 3, 103-109.
32. Shobab LA, Hsiung GY, Feldman HH (2005) Cholesterol in Alzheimers disease. Lancet Neurol 4, 841-852.
33. Patterson C, FeightnerJW, Garcia A, Hsiung JYR, MacKnight C, Sadovnick AD (2008) Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ 178, 548-556. (Pubitemid 351413998)
34. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Küstermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Brüning JC (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 101, 3100-3105. (Pubitemid 38327741)
35. Roriz-Filho JS, Śa-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves MLF, Moriguti JC, Roriz-Cruz M (2009) (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 1792, 432-443.
36. Panza F, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, Santamato A, DOnofrio G, Seripa D, Sancarlo D, Pilotto A, Solfrizzi V (2010) Metabolic syndrome and cognitive impairment: Current epidemiology and possible underlying mechanisms. J Alzheimers Dis 21, 691-724.
37. Kuljis RO, Salkovíc-Petrisíc M (2011) Dementia, diabetes, Alzheimers disease, and insulin resistance in the brain: Progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics. J Alzheimers Dis 25, 29-41.
38. Lutz MW, Crenshaw DG, Saunders AM, Roses AD (2011) The importance of being connected. J Alzheimers Dis 24, 247-251.
39. Mateos L, Ismail MAM, Gil-Bea FJ, Leoni V, Winblad B, Björkhem I, Cedazo-Minguez A (2011) Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimers disease. J Alzheimers Dis 24, 669-679.
40. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, DAgostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimers disease. N Engl J Med 346, 476-483. (Pubitemid 34441738)
41. Hooshmand B, Solomon A, Kåreholt I, Leiviskä J, Rusanen M, Ahtiluoto S, Winblad B, Laatikainen T, Soininen H, Kivipelto M (2010) Homocysteine and holotranscobalamin and the risk of Alzheimer disease: A longitudinal study. Neurology 75, 1408-1414.
42. Chrissobolis S, Miller AA, Drummond GR, Kemp-Harper BK, Sobey CG (2011) Oxidative stress and endothelial dysfunction in cerebrovascular disease.Front Biosci 16, 1733-1745.
43. Park L, Wang G, Zhou P, Zhou J, Pitstick R, Previti ML, Younkin L, Younkin SG, Van Nostrand WE, Cho S, Anrather J, Carlson GA, Iadecola C (2011) Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc Natl Acad Sci U S A 108, 5063-5068.
44. Maccioni RB, Faŕas G, Morales I, Navarrete L (2010) The revitalized tau hypothesis on Alzheimers disease. Arch Med Res 41 226-231.
45. Shcherbatykh I, Carpenter DO (2007) The role of metals in the etiology of Alzheimers disease. J Alzheimers Dis 11, 191-205. (Pubitemid 47010984)
46. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P (2008) Conversion from cognitive health to mild cognitive impairment and Alzheimers disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging 29, 1-11. (Pubitemid 350102708)
47. Blasko I, Kemmler G, Jungwirth S, Wichart I, Weissgram S, Jellinger K, Tragl KH, Fischer P (2011) Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors. J Neural Transm 118, 663-672.
48. McGeer EG, McGeer PL (2010) Neuroinflammation in Alzheimers disease and mild cognitive impairment: A field in its infancy. J Alzheimers Dis 19, 355-361.
49. Aliev G, Smith MA, de la Torre JC, Perry G (2004) Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimers disease. Mitochondrion 4, 649-663. (Pubitemid 39650918)
50. Salmina AB, Inzhutova AI, Malinovskaya NA, Petrova MM (2010) Endothelial dysfunction and repair in Alzheimer-type neurodegeneration: Neuronal and glial control. J Alzheimers Dis 22, 17-36.
51. de la Torre JC, Aliev G (2005) Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: Spatial memory and immunocytochemical changes. J Cereb Blood Flow Metab 25, 663-672. (Pubitemid 40705602)
52. Liu D, Pitta M, Lee JH, Ray B, Lahiri DK, Furukawa K, Mughal M, Jiang H, Villarreal J, Cutler RG, Greig NH, Mattson MP (2010) The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimers disease. J Alzheimers Dis 22, 443-457.
53. Aliev G (2002) Is non-genetic Alzheimers disease a vascular disorder with neurodegenerative consequences? J Alzheimers Dis 4, 513-516. (Pubitemid 36142840)
54. Mariani E, Polidori MC, Cherubini A, Mecocci P (2005) Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. J Chromatogr B Analyt Technol Biomed Life Sci 827, 65-75. (Pubitemid 41551598)
55. Polidori MC (2004) Oxidative stress and risk factors of Alzheimers disease: Clues to prevention and therapy. J Alzheimers Dis 6, 185-191. (Pubitemid 38560255)
56. McKahn G, Drachman D, Folstein MF, Katzman R, Proce D, Stadlan EM (1984) Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimers disease. Neurology 34, 939-944. (Pubitemid 14076461)
57. Viswanathan A, Rocca WA, Tzourio C (2009) Vascular risk factors and dementia. How to move forward? Neurology 72, 368-374.
58. George DR, Whitehouse PJ, Ballenger J (2011) The evolving classification of dementia: Placing the DSM-V in a meaningful historical and cultural context and pondering the future of Alzheimers. Cult Med Psychiatry 35, 417-435.
59. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, OBrien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimers disease: A new lexicon. Lancet Neurol 9, 1118-1127.
60. Britton GB, Rao KSJ (2011) Cognitive aging and early diagnosis challenges in Alzheimers disease. J Alzheimers Dis 24, 153-159.
61. No authors listed Recent papers on Alzheimer disease identified by leaders in the field as notable advances (2006) Nat Med 12, 767.
62. Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimers disease: Recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 7, 270-279.
63. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimers disease: Recommendations from the national institute on aging-Alzheimers association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 7, 280-292.
64. Macready AL, Butler LT, Kennedy OB, Ellis JA, Williams CM, Spencer JP (2010) Cognitive tests used in chronic adult human randomised controlled trial micronutrient and phytochemical intervention studies. Nutr Res Rev 23, 200-229.
65. Barnes DE, Yaffe K (2009) Predicting dementia: Role of dementia risk indices. Future Neurol 4, 555-560.
66. de laTorre JC (2010)Vascular risk factor detection and control may prevent Alzheimers disease. Ageing Res Rev 9, 218-225.